The use of tacrolimus and mycophenolate mofetil after cardiac transplantation

Current Opinion in Cardiology

Volumn 12, Issue 2, 1997, Pages 161-165

  Taylor, David O ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; FK 506 BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ADVERSE DRUG REACTION; ANEMIA; ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DRUG ABSORPTION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLUCOSE INTOLERANCE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY GRAFT REJECTION; LEUKOPENIA; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREMOR; VOMITING;

EID: 0030940788     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199703000-00011     Document Type: Article

References (33)

1. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhura M: FK-506, a novel immunosuppressant isolated from a Streptomyces: I. Fermentation, isolation and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987, 40:1249-1255.
2. Ochiai T, Nakajima K, Nagata M: Effect of a new immunosuppressive agent, FK-506, on heterotopic cardiac allotransplantation in the rat Transplant Proc 1987, 19:1284-1286.
3. Thomson AW: FK-506: profile of an important new immunosuppressant. Transplant Rev 1990, 4:1-13.
4. Harding MW, Galal A, Uehling DE, Schreiber SL: A receptor for the immunosuppressant FK-506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989, 341:758-760.
5. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66:807-815.
6. U. S. Multicenter FK506 Liver Study Group: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994, 331:1110-1115.
7. European FK506 Multicentre Liver Study Group: Randomized trial comparing tacrolimus (FK506) and cyclosporin in the prevention of liver allograft rejection. Lancet 1994, 344:423-428.
8. FK506 US Kidney Transplant Multicenter Study Group: FK506 in kidney transplantation: results of the US randomized, comparative, phase III study [abstract]. American Society of Transplant Physicians-15th Annual Scientific Sessions Program. Dallas: American Society of Transplant Physicians; 1996:171.
9. Armitage JM, Kormos RL, Morita S, Fung J, Marrone GC, Hardesty RL, Griffith BP, Starzl TE: Clinical trial of FK506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg 1992, 54:205-211.
10. Pham SM, Kormos RL, Hattler BG, Kawai A, Tsamandas A, Demetris A, Murali S, Fricker FJ, Chang H, Jain A, et al.: A prospective trial of tacrolimus (FK506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg 1996, 111:764-772. This is the largest series reported to date of cardiac transplant recipients treated with tacrolimus as primary therapy. Unfortunately limited by its uncontrolled nature, it still provides useful information regarding the general efficacy and side-effect profile of tacrolimus in cardiac transplant recipients.
11. Reichart B, Meiser B, Vigano M, Rinaldi M, Yacoub M, Banner N, Hetzer R, Hummel M, Gandjbakhch J, Dorent R: Tacrolimus (FK506) vs cyclosporin in heart transplantation: results from a randomized, European, multicentre pilot study. J Heart Lung Transplant 1997, 16:43.
12. Taylor DO, Barr ML, Radovancevic B, Mentzer RM, Smart FW, Tolman DE, Frazier OH, Renlund DG, Young JB, Van Veldhuisen P: A comparison of tacrolimus- and cyclosporine-based immunosuppression in cardiac transplantation. J Heart Lung Transplant 1997, 16:72.
13. Gosio B: Ricerche bacteriologiche e chimiche sulle alterazioni del mais. Riv Igiene Sanita Pubblica 1896, 7:825-868.
14. Alsberg CL, Black OF: Contribution to the study of maize deterioration. Biochemical and toxocological investigations of Penicillium puberlulum and Penicillin stoloniferum. US Dept Agr Plant Industry Bull 1913, 270:7-48.
15. Florey HW, Gilliver K, Jennings MA, Sanders AG: Mycophenolic acid-an antibiotic from Penicillium brevi-compactum Dierckx. Lancet 1946, 1:46-49.
16. Williams RH, Lively DH, DeLong DC, Cline JC, Sweeney MJ, Poore GA, Larsen SH: Mycophenolic acid: antiviral and antitumor properties. J Antibiotics 1968, 21:463-464.
17. Mitsui A, Suzuki S: Immunosuppressive effect of mycophenolic acid. J Antibiotics 1969, 22:358-363.
18. Jones EL, Epinette WW, Hackney VC, Menendez L, Frost P: Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol 1975, 65:537-542.
19. Marinari R, Fleischmajer R, Schragger AH, Rosenthal AL: Mycophenolic acid in the treatment of psoriasis. Arch Dermatol 1977, 113:930-932.
20. Brewin TB, Cole MP, Jones CTA, Platt DS, Todd IDH: Mycophenolic acid (NSC-129185): preliminary clinical trials. Cancer Chemother Rep 1972, 56:83-87.
21. Allison AC, Hovi T, Watts RWE, Webster ADB: The role of de novo purine synthesis in lymphocyte transformation. Ciba Found Symp 1977, 48:207-224.
22. Allison AC, Hovi T, Watts RWE, Webster ADB: Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of de novo purine synthesis in lymphocyte transformation. Lancet 1975, 2:1179-1183.
23. Franklin TJ, Cook JM: The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969, 113:515-524.
24. Lee WA, Gu L, Miksztal AR, Chu M, Kwan Leung, Nelson PH: Bioavailability improvement of mycophenolic acid through amino ester derivation. Pharm Res 1990, 7:161-166.
25. Sweeney MJ, Hoffman DH, Esterman MA: Metabolism and biochemistry of mycophenolic acid. Cancer Res 1972, 32:1803-1809.
26. Sollinger HW, Deierhoi MH, Belzer FO, Diethelm AG, Kauffman RS: RS-61443: a phase I clinical trial and pilot rescue study. Transplantation 1992, 53:428-432.
27. Sollinger HW, Belzer FO, Deierhoi MH, Diethelm AG, Gonwa TA, Kauffman RS, Klintmalm GB, McDiarmid SV, Robert J, Rosenthal JT, et al.: RS-61443 (mycophenolate mofetil): a multicenter study for refractory kidney transplant rejection. Ann Surg 1992, 216:513-519.
28. Klintmalm GB, Ascher NL, Busuttil RW, Deierhoi M, Gonwa TA, Kauffman RS, McDiarmid SV, Poplawski S, Sollinger H, Roberts J: RS-61443 for treatment-resistant human liver rejection. Transplant Proc 1993, 25:697.
29. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996, 61:1029-1037. To date, this is the largest randomized, controlled trial of MMF in solid-organ (kidney) transplantation and as such serves as a reference for general efficacy and side-effect data for MMF in solid-organ transplant recipients.
30. Ensley RD, Bristow MR, Olsen SL, Taylor DO, Hammond EH, O'Connell JB, Dunn D, Osburn L, Jones KW, Kauffman RS, et al.: The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 1993, 56:75-82.
31. Kobashigawa JA, Renlund DG, Olsen SL, Stevenson LW, McDiarmid SV, Swanson S, Albanese E, Taylor DO, Dunn D, Brownfield E, et al.: Initial results of RS-61443 for refractory cardiac rejection [abstract]. J Am Coll Cardiol 1992, 19:203A.
32. Kirklin JK, Bourge RC, Naftel DC, Morrow WR, Deierhoi MH, Kauffman RS, White-Williams C, Nomberg RI, Holman WL, Smith DC: Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. J Heart Lung Transplant 1994, 13:444-450.
33. Taylor DO, Ensley RD, Olsen SL, Dunn D, Renlund DG: Mycophenolate mofetil (RS-61443): preclinical, clinical and three-year experience in heart transplantation. J Heart Lung Transplant 1994, 13:571-582.